Skip to Content



(tel BI vyoo deen)

Index Terms

  • L-Deoxythymidine
  • LdT

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Tyzeka: 600 mg

Brand Names: U.S.

  • Tyzeka

Pharmacologic Category

  • Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HBV)


Telbivudine, a synthetic thymidine nucleoside analogue (L-enantiomer of thymidine), is intracellularly phosphorylated to the active triphosphate form, which competes with the natural substrate, thymidine 5'-triphosphate, to inhibit hepatitis B viral DNA polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA replication.


Vd > total body water


No metabolites detected


Urine (~42% as unchanged drug)

Time to Peak

1-4 hours

Half-Life Elimination

Terminal: 40-49 hours

Protein Binding


Use: Labeled Indications

Treatment of chronic hepatitis B with evidence of viral replication and either persistent transaminase elevations or histologically-active disease


Concurrent use with peginterferon alfa-2a

Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to telbivudine or any component of the formulation

Dosing: Adult

Chronic hepatitis B: Oral: 600 mg once daily.

Treatment duration (AASLD practice guidelines [Lok, 2009]):

Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat ≥1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for ≥6 months after HBeAg seroconversion.

HBeAg negative chronic hepatitis: Treat >1 year until hepatitis B surface antigen (HBsAg) clearance.

Note: Patients not achieving <2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy should either receive additional treatment or be switched to an alternative therapy.

Dosing: Pediatric

Chronic hepatitis B: Oral: Adolescents ≥16 years: Refer to adult dosing.

Dosing: Renal Impairment

CrCl ≥50 mL/minute: No dosage adjustment is necessary.

CrCl 30-49 mL/minute: 600 mg every 48 hours

CrCl <30 mL/minute (not requiring dialysis): 600 mg every 72 hours

End-stage renal disease (ESRD): 600 mg every 96 hours

Hemodialysis: Administer after dialysis session

Dosing: Hepatic Impairment

No dosage adjustment necessary.


May be administered without regard to food.

Dietary Considerations

May be taken without regard to food.


Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

Interferon Alfa-2b: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. Avoid combination

Peginterferon Alfa-2a: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. Avoid combination

Peginterferon Alfa-2b: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. Avoid combination

Adverse Reactions


Central nervous system: Fatigue (13%)

Neuromuscular & skeletal: Increased creatine phosphokinase (79%; grades 3/4: 16%, most asymptomatic and transient)

1% to 10%:

Central nervous system: Headache (10%), dizziness (4%), fever (4%), insomnia (3%)

Dermatologic: Skin rash (4%), pruritus (2%)

Endocrine & metabolic: Increased serum lipase (grades 3/4: 2%)

Gastrointestinal: Diarrhea (6%), abdominal pain (3% to 6%), nausea (5%), abdominal distension (3%), dyspepsia (3%)

Hematologic & oncologic: Neutropenia (grades 3/4: 2%)

Hepatic: Increased serum ALT (grades 3/4: 5% to 7%), increased serum AST (grades 3/4: 6%)

Infection: Exacerbation of hepatitis B (2%)

Neuromuscular & skeletal: Arthralgia (4%), back pain (4%), myalgia (3%)

Respiratory: Cough (6%), pharyngolaryngeal pain (5%)

<1% (Limited to important or life-threatening): Hepatomegaly, hyperbilirubinemia, hypoesthesia, increased amylase, lactic acidosis, liver steatosis, myopathy, myositis, paresthesia, peripheral neuropathy, rhabdomyolysis, thrombocytopenia

ALERT: U.S. Boxed Warning

Lactic acidosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with antiretrovirals.

Chronic hepatitis:

Severe, acute exacerbations of hepatitis B have been reported in patients who have discontinued anti–hepatitis B therapy, including telbivudine. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue anti–hepatitis B therapy. If appropriate, resumption of anti–hepatitis B therapy may be warranted.


Concerns related to adverse effects:

• Lactic acidosis/hepatomegaly: [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases; use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).

• Myopathy: Use has been associated with myopathy (unexplained muscle aches and/or muscle weakness in conjunction with serum creatine kinase increases) several weeks to months after initiation of telbivudine; interrupt therapy if myopathy is suspected and discontinue therapy if myopathy is diagnosed. Patients taking concomitant medications associated with myopathy should be monitored closely.

• Peripheral neuropathy: May occur alone or in combination with pegylated interferon alfa-2a (concurrent use is contraindicated) or possibly other interferons. Symptoms have been observed within 3 months after initiation of therapy. Interrupt treatment for suspected peripheral neuropathy and discontinue if confirmed; symptoms may be reversible with discontinuation.

Disease-related concerns:

• Chronic hepatitis B: [U.S. Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation. Monitor liver function several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.

• Human immunodeficiency virus: Telbivudine does not exhibit any clinically-relevant activity against HIV type 1.

• Renal impairment: Use caution in patients with moderate-to-severe renal dysfunction and end stage renal disease (ESRD); dosing adjustment required (CrCl <50 mL/minute).

Special populations:

• African-American or Hispanic patients: Safety and efficacy have not been established in Black/African-American or Hispanic patients.

• Coinfections: Safety and efficacy have not been studied in patients coinfected with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV).

• Liver transplant recipients: Safety and efficacy in liver transplant patients have not been established; monitor renal function in patients receiving concurrent therapy of cyclosporine or tacrolimus.

Other warnings/precautions:

• Appropriate Use: Not recommended as first-line therapy of chronic HBV due to high rate of resistance; use may be appropriate in short-term treatment of acute HBV (Lok, 2009).

• Resistance: Cross-resistance among hepatitis B antivirals may develop; use caution in patients failing previous lamivudine therapy.

Monitoring Parameters

LFTs (eg, AST and ALT) periodically during therapy and for several months following discontinuation of therapy; renal function prior to initiation and periodically during treatment; signs and symptoms of peripheral neuropathy (eg, weakness, paresthesia, leg pain) or myopathy (eg, unexplained muscle pain, tenderness or weakness); serum creatine kinase; HBV DNA (every 3-6 months during therapy); HBeAg and anti-HBe signs/symptoms of HBV relapse/exacerbation after discontinuation of therapy.

Pregnancy Risk Factor


Pregnancy Considerations

Adverse events were not observed in animal reproduction studies. Based on available information, telbivudine may be used to treat hepatitis b during pregnancy (Liu, 2013). Health professionals are encouraged to contact the antiretroviral pregnancy registry to monitor outcomes of pregnant women exposed to antiretroviral medications (1-800-258-4263).

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience abdominal pain, headache, loss of strength and energy, cough, nausea, or diarrhea. Have patient report immediately to prescriber signs of liver problems (dark urine, feeling tired, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin or eyes), signs of too much lactic acid in the blood (lactic acidosis; fast breathing, fast heartbeat, abnormal heartbeat, vomiting, drowsiness, shortness of breath, feeling very tired or weak, severe dizziness, feeling cold, or muscle pain or cramps), burning or numbness feeling, change in balance, abnormal gait, urinary retention, change in amount of urine passed, chills, pharyngitis, abdominal edema, muscle pain, or muscle weakness (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.